Jane J Kim1. 1. Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, Boston, MA, USA. jkim@hsph.harvard.edu
Abstract
BACKGROUND: A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men. High-risk populations such as men who have sex with men (MSM) might especially benefit from vaccination. I aimed to estimate the cost-effectiveness of HPV vaccination of MSM in the USA. METHODS: I constructed decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination (against types 6, 11, 16, and 18) for prevention of HPV-related anal cancer and genital warts. The model parameters that were varied were age at vaccination (12 years, 20 years, and 26 years), previous exposure to vaccine-targeted HPV types, and prevalence of HIV-1. I used the models to conduct sensitivity analyses, including duration of vaccine protection, vaccine cost, and burden of anal cancer and genital warts. FINDINGS: In a scenario of HPV vaccination of MSM at 12 years of age without previous exposure to HPV, compared with no vaccination, vaccination cost US$15,290 per quality-adjusted life-year gained. In scenarios where MSM are vaccinated at 20 years or 26 years of age, after exposure to HPV infections, the cost-effectiveness ratios worsened, but were less than $50,000 per quality-adjusted life-year under most scenarios. For example, HPV vaccination of MSM at 26 years cost $37,830 per quality-adjusted life-year when previous exposure to all vaccine-targeted HPV types was assumed to be 50%. Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM. INTERPRETATION: HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer. FUNDING: US National Cancer Institute.
BACKGROUND: A vaccine targeting human papillomavirus (HPV) types 16 and 18, which are associated with 80% of anal cancers, is efficacious in men. High-risk populations such as men who have sex with men (MSM) might especially benefit from vaccination. I aimed to estimate the cost-effectiveness of HPV vaccination of MSM in the USA. METHODS: I constructed decision-analytic models to estimate the direct health and economic outcomes of HPV vaccination (against types 6, 11, 16, and 18) for prevention of HPV-related anal cancer and genital warts. The model parameters that were varied were age at vaccination (12 years, 20 years, and 26 years), previous exposure to vaccine-targeted HPV types, and prevalence of HIV-1. I used the models to conduct sensitivity analyses, including duration of vaccine protection, vaccine cost, and burden of anal cancer and genital warts. FINDINGS: In a scenario of HPV vaccination of MSM at 12 years of age without previous exposure to HPV, compared with no vaccination, vaccination cost US$15,290 per quality-adjusted life-year gained. In scenarios where MSM are vaccinated at 20 years or 26 years of age, after exposure to HPV infections, the cost-effectiveness ratios worsened, but were less than $50,000 per quality-adjusted life-year under most scenarios. For example, HPV vaccination of MSM at 26 years cost $37,830 per quality-adjusted life-year when previous exposure to all vaccine-targeted HPV types was assumed to be 50%. Outcomes were most sensitive to variations in anal cancer incidence, duration of vaccine protection, and HIV prevalence in MSM. INTERPRETATION:HPV vaccination of MSM is likely to be a cost-effective intervention for the prevention of genital warts and anal cancer. FUNDING: US National Cancer Institute.
Authors: Wolfgang C Winkelmayer; Milton C Weinstein; Murray A Mittleman; Robert J Glynn; Joseph S Pliskin Journal: Med Decis Making Date: 2002 Sep-Oct Impact factor: 2.583
Authors: Hans-Georg Eichler; Sheldon X Kong; William C Gerth; Panagiotis Mavros; Bengt Jönsson Journal: Value Health Date: 2004 Sep-Oct Impact factor: 5.725
Authors: Peter V Chin-Hong; Eric Vittinghoff; Ross D Cranston; Susan Buchbinder; Daniel Cohen; Grant Colfax; Maria Da Costa; Teresa Darragh; Eileen Hess; Franklyn Judson; Beryl Koblin; Maria Madison; Joel M Palefsky Journal: J Infect Dis Date: 2004-11-10 Impact factor: 5.226
Authors: Mark Bower; Tom Powles; Tom Newsom-Davis; Christina Thirlwell; Justin Stebbing; Sundihya Mandalia; Mark Nelson; Brian Gazzard Journal: J Acquir Immune Defic Syndr Date: 2004-12-15 Impact factor: 3.731
Authors: D G Fryback; E J Dasbach; R Klein; B E Klein; N Dorn; K Peterson; P A Martin Journal: Med Decis Making Date: 1993 Apr-Jun Impact factor: 2.583
Authors: Margaret Rosario; Heather L Corliss; Bethany G Everett; Sari L Reisner; S Bryn Austin; Francisco O Buchting; Michelle Birkett Journal: Am J Public Health Date: 2013-12-12 Impact factor: 9.308
Authors: Christopher W Wheldon; Ellen M Daley; Eric R Walsh-Buhi; Julie A Baldwin; Alan G Nyitray; Anna R Giuliano Journal: Am J Mens Health Date: 2016-06-06
Authors: Andrew J Leidner; Neil Murthy; Harrell W Chesson; Matthew Biggerstaff; Charles Stoecker; Aaron M Harris; Anna Acosta; Kathleen Dooling; Carolyn B Bridges Journal: Vaccine Date: 2018-12-04 Impact factor: 3.641